Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma

Annals of Surgery

Volumn 251, Issue 6, 2010, Pages 1003-1010

  Jamieson, Nigel B ^a,b   Foulis, Alan K ^a   Oien, Karin A ^a,b   Going, James J ^a,b   Glen, Paul ^a   Dickson, Euan J ^a   Imrie, Clem W ^a   McKay, Colin J ^a   Carter, Ross ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ADJUVANT THERAPY; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MINIMAL RESIDUAL DISEASE; MORTALITY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUMOR VOLUME; UNITED KINGDOM;

ADENOCARCINOMA; AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; SURVIVAL RATE;

EID: 77953027002     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181d77369     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer database. J Am Coll Surg. 1999;189:1-7.
3. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995;221:721-731.
4. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gas-trointest Surg. 2000;4:567-579.
5. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemora-diation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234:758-768.
6. Jarufe NP, Coldham C, Mayer AD, et al. Favorable prognostic factors in a large UK experience of adenocarcinoma of the head of the pancreas and periampullary region. Dig Surg. 2004;21:202-209.
7. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenecto- mies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199-1210.
8. Bouvet M, Gamagami RA, Gilpin EA, et al. Factors influencing survival after resection for periampullary neoplasms. Am J Surg. 2000;180:13-17.
9. Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg. 2004;139:718-725; discussion 725-727.
10. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocar-cinoma. Ann Surg. 2007;246:52-60.
11. Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocar-cinoma. Br J Surg. 2004;91:586-594.
12. Kayahara M, Nagakawa T, Ueno K, et al. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993;72:2118-2123.
13. Van den Broeck A, Sergeant G, Ectors N, et al. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009;35:600-604.
14. Yeo CJ, Cameron JL. Prognostic factors in ductal pancreatic cancer. Lange-nbecks Arch Surg. 1998;383:129-133.
15. Verbeke CS, Leitch D, Menon KV, et al. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93:1232-1237.
16. Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15:1651-1660.
17. Butturini G, Stocken DD, Wente MN, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008;143:75-83.
18. Sobin LH. International Union Against Cancer: TNM Classification of Malignant Tumors. 5th ed. New York, NY: Wiley-Liss; 1997
19. The Royal College of Pathologists. Standards and Minimum Datasets for Reporting Cancers. Minimum Dataset for the Histopathological Reporting of Pancreatic, Ampulla of Vater and Bile Duct Carcinoma. London, United Kingdom: The Royal College of Pathologists; 2002.
20. Pissas A. Anatomoclinical and anatomosurgical essay on the lymphatic circulation of the pancreas. Anat Clin. 1984;6:255-280.
21. Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004;40:549-558.
22. Nagakawa T, Sanada H, Inagaki M, et al. Long-term survivors after resection of carcinoma of the head of the pancreas: significance of histologically curative resection. J Hepatobiliary Pancreat Surg. 2004;11:402-408.
23. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemora-diotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001;5:121-130
24. Exocrine pancreas. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. Chicago, IL: Springer; 2002:157-164.
25. Luttges J, Schemm S, Vogel I, et al. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochem-ical assessment of proliferation. J Pathol. 2000;191:154-161.
26. van Roest MH, Gouw AS, Peeters PM, et al. Results of pancreaticoduode- nectomy in patients with periampullary adenocarcinoma: perineural growth more important prognostic factor than tumor localization. Ann Surg. 2008; 248:97-103.
27. Allema JH, Reinders ME, van Gulik TM, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer. 1995;75:2069-2076.
28. Sasson AR, Hoffman JP, Ross EA, et al. En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg. 2002;6:147-157.
29. Westgaard A, Tafjord S, Farstad IN, et al. Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor. BMC Cancer. 2008;8:5.
30. Campbell F, Smith RA, Whelan P, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009;55:277-283.
31. Khalifa MA, Maksymov V, Rowsell C. Retroperitoneal margin of the pan-creaticoduodenectomy specimen: anatomic mapping for the surgical pathologist. Virchows Arch. 2009;454:125-131.
32. Verbeke CS. Resection margins and R1 rates in pancreatic cancer\are we there yet? Histopathology. 2008;52:787-796.
33. Wasserberg N, Gutman H. Resection margins in modern rectal cancer surgery. J Surg Oncol. 2008;98:611-615.
34. Tsuchiya R, Noda T, Harada N, et al. Collective review of small carcinomas of the pancreas. Ann Surg. 1986;203:77-81.
35. Schmidt CM, Glant J, Winter JM, et al. Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma. Surgery. 2007;142:572-578.
36. Horiguchi A, Ishihara S, Ito M, et al. Pancreatoduodenectomy in which dissection of the efferent arteries of the head of the pancreas is performed first. J Hepatobiliary Pancreat Surg. 2007;14:575-578.
37. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277.
38. Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomized adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92:1372-1381.